Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | VP FINANCE & ACCTG, TREASURER | February 12, 2021 | February 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date February 12, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2031-02-12 | Direct | 18,849 |
Reported balance
After 2021-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-12 · Grant · Acquired 18,849 · Balance 18,849 F1: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2: The options vest and become exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 12, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F2: The options vest and become exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 12, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 18,849 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000736 · form4-02172021_030216.xml · derivative · entry 1 MacDonald Stephen G. · CIK 0001839189 · VP FINANCE & ACCTG, TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,849 Underlying: Common Stock · 18,849 shares Expires 2031-02-12 F1 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 12, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.